1  Karol M Cordoba; Irantzu Serrano-Mendioroz; Daniel Jerico; et al; (AC);. (13/14). 2022. Recombinant porphobilinogen deaminase targeted to the liver corrects enzymopenia in a mouse model of acute intermittent porphyria   Science Translational Medicine. 14-627, pp.eabc0700 IF=17.96 Co-autor senior. WOS (0) https://doi.org/10.1126/ scitranslmed.abc0700

2 Itziar Otano; Arantza Azpilicueta; Javier Glez-Vaz; et al; (AC);. (21/ 22). 2021. CD137 (4-1BB) costimulation of CD8+ T cells is more potent when provided in cis than in trans with respect to CD3-TCR stimulation  Nature Communications.10-1, pp.7296 IF=14.92 Autor de correspondecia. WOS (0) https://doi.org/10.1038/s41467-021-27613-w

3  Segues, Aina; van Duijnhoven, Sander M. J.; Parade, Marc; et al; Berraondo, Pedro; van Elsas, Andrea.  (8/9).  2021.  Generation and characterization of novel co-stimulatory anti-mouse TNFR2 antibodies   JOURNAL OF IMMUNOLOGICAL METHODS.  499,  pp.113173-IF=2.303.  ISSN 0022-1759.  https://doi.org/10.1016/ j.jim.2021.113173

4 Alvarez, Maite; Molina, Carmen; De Andrea, Carlos E.; et al; Berraondo, Pedro; Melero, Ignacio. (15/17). 2021. Intratumoral co-injection of the poly I:C-derivative BO-112 and a STING agonist synergize to achieve local and distant anti-tumor efficacy JOURNAL FOR IMMUNOTHERAPY OF CANCER. 9-11, pp.e002953-IF=13.751.  https:// doi.org/10.1136/jitc-2021-002953

5  Cabo, Mariona; Santana-Hernandez, Sara; Costa-Garcia, Marcel; et al; Berraondo, Pedro; Muntasell, Aura.  (13/17).  2021.  CD137 costimulation counteracts TGFbeta inhibition of NK-cell antitumor function.Cancer immunology research.  9-12,  pp.1476-1490 IF=11.151.  ISSN 2326-6074.  WOS (0)  https:// doi.org/10.1158/2326-6066.CIR-21-0030

6  Arce, Cristina; Rodriguez-Rovira, Isaac; De Rycke, Karo; et al; Berraondo, Pedro; Egea, Gustavo.  (8/9).  2021.  Anti-TGF beta (Transforming Growth Factor beta) Therapy With Betaglycan-Derived P144 Peptide Gene Delivery Prevents the Formation of Aortic Aneurysm in a Mouse Model of Marfan Syndrome ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY.  LIPPINCOTT WILLIAMS & WILKINS. 41-9, pp.E440-E452 IF=8.313. ISSN 1079-5642. WOS (0) https:// doi.org/10.1161/ATVBAHA.121.316496

7  Teijeira, Alvaro; Garasa, Saray; Ochoa, Maria del Carmen; et al; Berraondo, Pedro; Melero, Ignacio.  (12/15).  2021.  Differential Interleukin-8 thresholds for chemotaxis and netosis in human neutrophils   EUROPEAN JOURNAL OF IMMUNOLOGY. WILEY. 51-9, pp.2274-2280 IF=5.532. ISSN 0014-2980. WOS (2) https:// doi.org/10.1002/eji.202049029 3

8  Merino, Maria; Lozano, Teresa; Casares, Noelia; et al; Berraondo, Pedro; Garrido, Maria J.(8/10).  2021.  Dual activity of PD-L1 targeted Doxorubicin immunoliposomes promoted an enhanced efficacy of the antitumor immune response in melanoma murine model   JOURNAL OF NANOBIOTECHNOLOGY. BMC. 19-1, pp.IF=10.435. ISSN 1477-3155. WOS (6) https:// doi.org/10.1186/s12951-021-00846-z

9  Solares, Isabel; Izquierdo-Sanchez, Laura; Morales-Conejo, Montserrat; et al; Berraondo, Pedro; Fontanellas, Antonio.  (11/12).  2021.  High Prevalence of Insulin Resistance in Asymptomatic Patients with Acute Intermittent Porphyria and Liver-Targeted Insulin as a Novel Therapeutic Approach BIOMEDICINES.  MDPI.  9-3,  pp.IF=6.081.  ISSN 2227-9059.  WOS (2)  https:// doi.org/10.3390/biomedicines9030255

10 Zalba, Sara; Belsue, Virginia; Topp, Brian; de Alwis, Dinesh; Alvarez, Maite; Troconiz, Inaki F.; Berraondo, Pedro; Garrido, Maria J. (AC). (8/8). 2021. Modulation of intratumoural myeloid cells, the hallmark of the anti-tumour efficacy induced by a triple combination: tumour-associated peptide, TLR-3 ligand and alpha-PD-1  BRITISH JOURNAL OF CANCER. pp.IF=7.57 Co-autor de correspondencia. ISSN 0007-0920. WOS (1) https:// doi.org/10.1038/s41416-020-01239-z

11 Ardaiz, Nuria; Gomar, Celia; Vasquez, Marcos; et al; Berraondo, Pedro (AC). (11/11). 2021. Insulin Fused to Apolipoprotein A-I Reduces Body Weight and Steatosis in DB/DB Mice   FRONTIERS IN PHARMACOLOGY.  11,  pp.591293 IF=5.81 Autor de correspondencia. ISSN 1663-9812. WOS (1) https://doi.org/10.3389/fphar.2020.591293

12 Tenesaca, Shirley; Vasquez, Marcos; Alvarez, Maite; et al; Berraondo, Pedro (AC).  (13/13).  2021.  Statins act as transient type I interferon inhibitors to enable the antitumor activity of modified vaccinia Ankara viral vectors   JOURNAL FOR IMMUNOTHERAPY OF CANCER. BMJ PUBLISHING GROUP. 9-7, pp.IF:13.75 Autor de correspondencia. ISSN 2051-1426. WOS (0) https://doi.org/10.1136/jitc-2020-001587

13  Hinterberger, Maria; Giessel, Raphael; Fiore, Giovanna; et al; Berraondo, Pedro; Medina-Echeverz, Jose.  (11/13).  2021.  Intratumoral virotherapy with 4-1BBL armed modified vaccinia Ankara eradicates solid tumors and promotes protective immune memory   JOURNAL FOR IMMUNOTHERAPY OF CANCER. 9, pp.IF=13.751. WOS (3) https://doi.org/10.1136/jitc-2020-001586

14 Fernandez-Sendin, Myriam; Di Trani, Claudia Augusta; Bella, Angela; et al; Berraondo, Pedro (AC).  (11/11).  2021.  Long-Term Liver Expression of an Apolipoprotein A-I Mimetic Peptide Attenuates Interferon-Alpha-Induced Inflammation and Promotes Antiviral Activity   FRONTIERS IN IMMUNOLOGY.  11,  pp.IF=7.561 Autor de correspondencia. ISSN 1664-3224. WOS (0) https://doi.org/10.3389/fimmu.2020.620283

15  Sancho-Araiz, Aymara; Zalba, Sara; Garrido, Maria J.; et al; Topp, Brian; Troconiz, Inaki F.(5/9).  2021.  Semi-Mechanistic Model for the Antitumor Response of a Combination Cocktail of Immuno-Modulators in Non-Inflamed (Cold) Tumors CANCERS. 13, pp.IF=6.639.  https://doi.org/10.3390/cancers13205049

16  Tenesaca, Shirley; Vasquez, Marcos; Fernandez-Sendin, Myriam; et al; Berraondo, Pedro (AC).  (11/11).  2020.  Scavenger Receptor Class B Type I is Required for 25-Hydroxycholecalciferol Cellular Uptake and Signaling in Myeloid Cells MOLECULAR NUTRITION & FOOD RESEARCH. 64-15, pp.e1901213 IF=5.914 Autor de correspondencia. ISSN 1613-4125. WOS (0) https://doi.org/10.1002/mnfr.201901213

17  Teijeira, Alvaro; Garasa, Saray; Gato, Maria; et al; Berraondo, Pedro; Melero, Ignacio. (24/26). 2020. CXCR1 and CXCR2 Chemokine Receptor Agonists Produced by Tumors Induce Neutrophil Extracellular Traps that Interfere with Immune Cytotoxicity  IMMUNITY. 52-5, pp.856-871 IF=31.745. ISSN 1074-7613. WOS (69) https:// doi.org/10.1016/j.immuni.2020.03.001

18 Otano, Itziar; Alvarez, Maite; Minute, Luna; et al; Berraondo, Pedro (AC); Melero, Ignacio. (12/13). 2020. Human CD8 T cells are susceptible to TNF-mediated activation-induced cell death   THERANOSTICS.  10-10,  pp.IF=11.556 Co-autor de correspondencia. ISSN 1838-7640. WOS (16) https://doi.org/10.7150/thno.41646 4

19  Minute, Luna; Teijeira, Alvaro; Sanchez-Paulete, Alfonso R.; et al; Berraondo, Pedro (AC); Melero, Ignacio.  (14/15).  2020.  Cellular cytotoxicity is a form of immunogenic cell death   JOURNAL FOR IMMUNOTHERAPY OF CANCER. 8-1, pp.e000325-IF=13.751. WOS (16) https://doi.org/10.1136/jitc-2019-000325

20 Alvarez, Maite; Simonetta, Federico; Baker, Jeanette; Morrison, Alyssa R.; Wenokur, Arlene S.; Pierini, Antonio; Berraondo, Pedro; Negrin, Robert S.2020. Indirect Impact of PD-1/PD-L1 Blockade on a Murine Model of NK Cell Exhaustion  FRONTIERS IN IMMUNOLOGY. 11. ISSN 1664-3224. WOS (3) https://doi.org/10.3389/fimmu.2020.00007

21  Merino M; Contreras A; Casares N; Troconiz IF; Ten Hagen TL; Berraondo P; Zalba S; Garrido MJ.  (6/8).  2019.  A new immune-nanoplatform for promoting adaptive antitumor immune response.Nanomedicine : nanotechnology, biology, and medicine. 17-17, pp.13-25. IF=6.5. ISSN 1549-9634. WOS (10) https://doi.org/10.1016/ j.nano.2018.12.016

22 Ochoa, Maria C.; Perez-Ruiz, Elisabeth; Minute, Luna; et al; Berraondo, Pedro (AC); Melero, Ignacio. (15/16). 2019. Daratumumab in combination with urelumab to potentiate anti-myeloma activity in lymphocyte-deficient mice reconstituted with human NK cells   ONCOIMMUNOLOGY.  8,  pp.IF=5.3. Co-autor de correspondencia.  ISSN 2162-402X. WOS (19) https://doi.org/10.1080/2162402X.2019.1599636

23 Etxeberria I; Bolaños E; Quetglas JI; et al; Berraondo P; Melero I. (23/ 25). 2019. Intratumor Adoptive Transfer of IL-12 mRNA Transiently Engineered Antitumor CD8+ T Cells.Cancer cell. 36, pp.613-629. IF=22.8.. ISSN 1535-6108. WOS (41) https:// doi.org/10.1016/j.ccell.2019.10.006

24  Schalper KA; Rodriguez-Ruiz ME; Diez-Valle R; et al; Berraondo P; Melero I.  (11/20).  2019.  Neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastoma.Nature medicine.  25-3,  pp.470-476 IF=32.6. ISSN 1078-8956. WOS (230) https://doi.org/10.1038/s41591-018-0339-5

25  Elisabeth Perez-Ruiz; Luna Minute; Itziar Itziar Otano; et al; (AC);.  (16/17).  2019.  Prophylactic TNF-alpha blockade unplugs efficacy and toxicity in dual CTLA-4/PD-1 immunotherapy.Nature. 569-7756, pp.428-432. IF=41.577. Co-autor de correspondencia. WOS (164) https://doi.org/10.1038/s41586-019-1162-y

26  Angela Aznar, M.; Molina, Carmen; Teijeira, Alvaro; et al; Melero, Ignacio.  (13/14).  2019.  Repurposing the yellow fever vaccine for intratumoral immunotherapy   EMBO Mol Med.  12-1,  pp.e10375. IF=8.8.  ISSN 0008-5472.  WOS (11) https://doi.org/10.1158/1538-7445.AM2019-1474

27  Rodriguez-Ruiz ME; Rodriguez I; Mayorga L; et al; Berraondo P; Melero I.  (11/15).  2019.  TGFbeta blockade enhances radiotherapy abscopal efficacy effects in combination with anti-PD1 and anti-CD137 immunostimulatory monoclonal antibodies.Molecular cancer therapeutics. 18-3, pp.621-631 IF=5.3. ISSN 1535-7163. WOS (39) https://doi.org/10.1158/1535-7163.MCT-18-0558

28 Vasquez, Marcos; Consuegra-Fernandez, Marta; Aranda, Fernando; et al; Berraondo, Pedro.  (13/13).  2019.  Treatment of Experimental Autoimmune Encephalomyelitis by Sustained Delivery of Low-Dose IFN-alpha   JOURNAL OF IMMUNOLOGY.  203-3,  pp.696-704. IF=4.7. Último autor..  ISSN 0022-1767.  WOS (3) https://doi.org/10.4049/jimmunol.1801462

29  Lei Jiang; Pedro Berraondo; Daniel Jerico; Lin T Guey; Ana Sampredro.  (2/23).  2018.  Systemic messenger RNA as an etiological treatment for acute intermittent porphyria   Nature Medicine.  24-12,  pp.1899-1909. IF=32.6. Primer coautor. ISSN 1546-170X. WOS (64) https://doi.org/10.1038/s41591-018-0199-z

30  ME Rodriguez-Ruiz; JL Perez-Gracia; I Rodriguez; et al; ;.  (13/ 20). 2018. Combined immunotherapy encompassing intratumoral poly-ICLC, dendritic-cell vaccination and radiotherapy in advanced cancer patients   ANNALS OF ONCOLOGY.  29-5,  pp.1312-1319. IF=5.3.  WOS (17)  https://doi.org/10.1093/annonc/ mdy089 5

31  Serrano-Mendioroz I; Sampedro A; Serna N; et al; Berraondo P; Fontanellas A.  (7/9).  2018.  Bioengineered PBGD variant improves the therapeutic index of gene therapy vectors for acute intermittent porphyria.Human molecular genetics. 27-21, pp.1312-1319. IF=4.9. ISSN 0964-6906. WOS (9) https://doi.org/10.1093/ hmg/ddy283

32  Ochoa, MC.; Minute, L.; López, A.; et al; Berraondo, P. (AC). (14/ 14).  2018.  Enhancement of antibody-dependent cellular cytotoxicity of cetuximab by a chimeric protein encompassing interleukin-15.Oncoimmunology. 7-2, pp.e1393597-IF=5,5. Autor de correspondencia..  ISSN 2162-4011.  WOS (17)  https:// doi.org/10.1080/2162402X.2017.1393597

33  Sánchez-Paulete AR; Teijeira Á; Quetglas JI; et al; Berraondo P; Melero I. (13/16).  2018.  Intratumoral Immunotherapy with XCL1 and sFlt3L Encoded in Recombinant Semliki Forest Virus-Derived Vectors Fosters Dendritic Cell-Mediated T-cell Cross-Priming.Cancer research.  78-23,  pp.6643-6654. IF=9.1.  ISSN 0008-5472.  WOS (37) https://doi.org/10.1158/0008-5472.CAN-18-0933

34  Serrano, I.; Sampedro, A.; Alegre, M.; Enriquez de Salamanca, R.; Berraondo, P.; Fontanellas, A.(5/6).  2017.  An inducible promoter responsive to different porphyrinogenic stimuli improves gene therapy vectors for acute intermittent porphyria.Human gene therapy.  29-4,  pp.480-491. IF=4.2.  ISSN 1557-7422.  WOS (10) https://doi.org/10.1089/hum.2017.056

35  Alvarez Sola, G.; Uriarte, I.; Latasa, MU.; et al; Berraondo, P.; Avila, MA.(14/17).  2017.  Engineered fibroblast growth factor 19 protects from acetaminophen-induced liver injury and stimulates aged liver regeneration in mice.Cell death & disease.  8-10,  pp.e3083-IF=5.3.  ISSN 2041-4889.  WOS (11)  https:// doi.org/10.1038/cddis.2017.480

36 Alvarez Sola, G.; Uriarte, I.; Latasa, MU.; et al; Berraondo, P.; Avila, MA.(20/22). 2017. Fibroblast growth factor 15/19 (FGF15/19) protects from diet-induced hepatic steatosis: development of an FGF19-based chimeric molecule to promote fatty liver regeneration.Gut. 66-10, pp.1818-1828. IF=17. ISSN 1468-3288. WOS (22) https:// doi.org/10.1136/gutjnl-2016-312975

37 Revisión bibliográfica.  Di Trani, Claudia Augusta; Fernandez-Sendin, Myriam; Cirella, Assunta; Segues, Aina; Olivera, Irene; Bolanos, Elixabet; Melero, Ignacio; Berraondo, Pedro (AC).  (8/8).  2021.  Advances in mRNA-based drug discovery in cancer immunotherapy EXPERT OPINION ON DRUG DISCOVERY.  17-1,  pp.41-53 IF=6.098.  ISSN 1746-045X. WOS (1) https://doi.org/10.1080/17460441.2021.1978972

38 Revisión bibliográfica.  Teijeira, Alvaro; Garasa, Saray; Ochoa, Maria C.; et al; Berraondo, Pedro; Melero, Ignacio.  (8/12).  2021.  IL8, Neutrophils, and NETs in a Collusion against Cancer Immunity and Immunotherapy   CLINICAL CANCER RESEARCH.  27-9,  pp.2383-2393 IF=12.531.  ISSN 1557-3265.  WOS (9)  https:// doi.org/10.1158/1078-0432.CCR-20-1319

39 Melero, Ignacio; Teijeira, Alvaro; Aranda, Fernando; Berraondo, Pedro (AC).  (4/4).  2021.  Firefighters for the Wrong Type of Inflammation in Tumors CANCER DISCOVERY.  11-10,  pp.2372-2374 IF=39.397.  ISSN 2159-8274.  https:// doi.org/10.1158/2159-8290.CD-21-1004

40 Melero, Ignacio; Berraondo, Pedro (AC).  (2/ 2).  2020.  4-1BB (CD137) in anticancer chimeras   JOURNAL OF EXPERIMENTAL MEDICINE. 217-12, pp.e20201562-IF=14.307. ISSN 0022-1007.  https://doi.org/10.1084/ jem.20201562

41 Etxeberria, Inaki; Olivera, Irene; Bolanos, Elixabet; Cirella, Asunta; Teijeira, Alvaro; Berraondo, Pedro; Melero, Ignacio. (6/7). 2020. Engineering bionic T cells: signal 1, signal 2, signal 3, reprogramming and the removal of inhibitory mechanisms CELLULAR & MOLECULAR IMMUNOLOGY.  17,  pp.IF=11.53.  ISSN 1672-7681. WOS (3) https://doi.org/10.1038/s41423-020-0464-1

42 Cirella, Assunta; Berraondo, Pedro; Di Trani, Claudia Augusta; Melero, Ignacio.  (2/4).  2020.  Interleukin-12 Message in a Bottle   CLINICAL CANCER RESEARCH.  26,  pp.IF=12.531.  ISSN 1078-0432.  WOS (0)  https:// doi.org/10.1158/1078-0432.CCR-20-3250 6

43 Berraondo P; Martini PGV; Avila MA; Fontanellas A.  (1/4).  2019.  Messenger RNA therapy for rare genetic metabolic diseases.Gut.  68-7,  pp.1323-1330 IF=17. Primer autor.  ISSN 0017-5749.  https:// doi.org/10.1136/gutjnl-2019-318269

44 Berraondo, Pedro (AC); Sanmamed, Miguel F.; Ochoa, Maria C.; et al; Melero, Ignacio.  (1/10).  2019.  Cytokines in clinical cancer immunotherapy BRITISH JOURNAL OF CANCER.  120-1,  pp.6-15.-IF=5.9. Primer autor y co-autor de correspondencia. ISSN 0007-0920. WOS (252) https://doi.org/10.1038/s41416-018-0328-y

45 Berraondo, Pedro; Ochoa, Maria C.; Olivera, Irene; Melero, Ignacio. (1/4). 2019. Immune Desertic Landscapes in Hepatocellular Carcinoma Shaped by beta-Catenin Activation  CANCER DISCOVERY. 9-8, pp.1003-1005 IF=39.397. ISSN 2159-8274. WOS (10) https://doi.org/10.1158/2159-8290.CD-19-0696

46 Fernando Pastor; Pedro Berraondo; Iñaki Etxeberria; Josh Frederick; Ugur Sahin; Eli Gilboa; Ignacio Melero. (2/7). 2018. An RNA toolbox for cancer immunotherapy   Nature Reviews Drug Discovery.  17-10,  pp.751-767. IF=50.16.  ISSN 1474-1784. WOS (82) https://doi.org/10.1038/nrd.2018.132

47 Pedro Berraondo; Iñaki Etxeberria; Mariano Ponz-Sarvise; Ignacio Melero.  (1/4).  2018.  Revisiting Interleukin-12 as a Cancer Immunotherapy Agent.Clinical cancer research.  24-12,  pp.2716-2718 IF=12.531.  WOS (40)  https:// doi.org/10.1158/1078-0432.CCR-18-0381

48 Etxeberria I; Teijeira A; Montuenga LM; Berraondo P; Melero I.  (4/5).  2018.  Epistatic Oncogenic Interactions Determine Cancer Susceptibility to Immunotherapy.Cancer discovery.  8,  pp.794-796 IF=39.397.  ISSN 2159-8274.  WOS (3) https://doi.org/10.1158/2159-8290.CD-18-0573

49 Alvarez Sola, G.; Uriarte, I.; Latasa, MU.; et al; Avila, MA.2017.  Bile acids, FGF15/19 and liver regeneration: From mechanisms to clinical applications.Biochimica et biophysica acta.  1864,  pp.1326-1334 IF=5.187.  ISSN 0006-3002. WOS (20) https://doi.org/10.1016/j.bbadis.2017.06.025

50 Marcos Vasquez; Marta Consuegra-Fernández; Fernando Aranda; Francisco Lozano; (AC).  (5/5).  2017.  Exploiting Scavenger Receptors in Cancer Immunotherapy: Lessons from CD5 and SR-B1   European Journal of Immunology.  47-7,  pp.1108-1118 IF=5.532.  WOS (15)  https://doi.org/10.1002/ eji.201646903

51 Berraondo, P.; Labiano, S.; Minute, L.; Etxeberria, I.; Vasquez, M.; Sanchez Arraez, A.; Teijeira, A.; Melero, I.(1/8). 2017. Cellular immunotherapies for cancer.Oncoimmunology. 6-5, pp.e1306619-IF=8.11. ISSN 2162-4011. WOS (14) https:// doi.org/10.1080/2162402X.2017.1306619

52 Ochoa, MC.; Minute, L.; Rodriguez, I.; Garasa, S.; Perez Ruiz, E.; Inogés, S.; Melero, I.; Berraondo, P. (AC).  (8/8).  2017.  Antibody-dependent cell cytotoxicity: immunotherapy strategies enhancing effector NK cells.Immunology and cell biology. 95-4, pp.347-355 IF=5.126. ISSN 1440-1711. WOS (94) https://doi.org/10.1038/ icb.2017.6